Cipla Limited Stock price

Equities

CIPLA

INE059A01026

Pharmaceuticals

Delayed NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
1,497 INR +2.30% Intraday chart for Cipla Limited +3.33% +20.11%
Sales 2024 * 258B 3.1B Sales 2025 * 280B 3.37B Capitalization 1,209B 14.5B
Net income 2024 * 41.44B 497M Net income 2025 * 45.06B 541M EV / Sales 2024 * 4.45 x
Net cash position 2024 * 58.72B 705M Net cash position 2025 * 83.96B 1.01B EV / Sales 2025 * 4.01 x
P/E ratio 2024 *
29.4 x
P/E ratio 2025 *
26.8 x
Employees 32,323
Yield 2024 *
0.57%
Yield 2025 *
0.61%
Free-Float 64.49%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.30%
1 week+3.33%
Current month+1.12%
1 month+1.35%
3 months+18.73%
6 months+28.60%
Current year+20.11%
More quotes
1 week
1 458.00
Extreme 1458
1 514.20
1 month
1 415.60
Extreme 1415.6
1 519.00
Current year
1 252.10
Extreme 1252.1
1 519.00
1 year
886.30
Extreme 886.3
1 519.00
3 years
790.25
Extreme 790.25
1 519.00
5 years
355.30
Extreme 355.3
1 519.00
10 years
355.30
Extreme 355.3
1 519.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 15-09-30
Director of Finance/CFO - 22-08-15
Chief Tech/Sci/R&D Officer - 85-12-31
Members of the board TitleAgeSince
Director/Board Member 72 13-07-15
Chairman 87 72-07-20
Director/Board Member 83 77-08-15
More insiders
Date Price Change Volume
24-03-28 1,497 +2.30% 2,110,407
24-03-27 1,463 -0.60% 1,642,266
24-03-26 1,472 -0.61% 1,635,695
24-03-22 1,481 +2.25% 1,746,930
24-03-21 1,449 +2.21% 1,699,939

Delayed Quote NSE India S.E., March 28, 2024 at 08:01 am EDT

More quotes
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
1,497 INR
Average target price
1,445 INR
Spread / Average Target
-3.46%
Consensus
  1. Stock
  2. Equities
  3. Stock Cipla Limited - NSE India S.E.